Abbott Steps Up Effort To Abandon Alere Deal
Abbott has asked a Delaware court to cancel its agreement to buy Alere for $5.8bn based on a series of financial and regulatory missteps by Alere. Alere, which earlier sued to force the merger to go through, plans to fight the suit.
You may also be interested in...
M&A Analysis: April Showers Big Name Acquisitions
M&A deals rained down in April with the highest number of acquisitions of the year to date. The month saw 14 M&A deals, up by four from March's total, but still down from the 16 deals recorded in April 2016.
Despite Legal Dispute, Abbott Set To Buy Alere for $5.3bn
Soon before it was set to take Alere to court in an attempt to break out of an acquisition deal, Abbott has reversed course and plans to buy the company for half a billion less than the original price tag.
Earnings Winners and Losers: BSX, EW, ABT, JNJ, SYK, ZBH
Many medtech companies reported their sales and earnings for all of 2016, along with projections for 2017, at the end of January or early February. Medtech Insight has examined their reports as well as the comments of the analysts who track these companies to highlight a few that had especially good years, some that had down years, and some lesser-known companies worth watching in the future.